Cumberland Pharmaceuticals Inc
- Last sale
- Nov 12, 2026 · +3.87%
- Market cap
- $98.52M
- 15M shares
- Filings
- 1,012
Q3 2026+17.6% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−36.3% FY24 yoy
- $98.52M
- 1.4×
- 2.9×
- 1.4×
- -1.00%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $44,521,431 | reported | |
| FY 2024 | 2024-12-31 | $37,867,945 | reported | |
| FY 2023 | 2023-12-31 | $39,552,507 | reported | |
| FY 2022 | 2022-12-31 | $42,010,949 revised | reported | |
| FY 2021 | 2021-12-31 | $35,045,259 | reported | |
| FY 2020 | 2020-12-31 | $35,840,673 | reported | |
| FY 2019 | 2019-12-31 | $32,407,845 revised | reported | |
| FY 2018 | 2018-12-31 | $28,803,961 revised | reported | |
| FY 2017 | 2017-12-31 | $40,376,563 revised | reported | |
| FY 2016 | 2016-12-31 | $32,478,185 revised | reported | |
| FY 2015 | 2015-12-31 | $900,000 | reported | |
| FY 2014 | 2014-12-31 | $600,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $263.48K | $263.48K | — | 14.96M sh | ±0.0% | 5.4% |
| FY2024 | — | $579.05K | $579.05K | — | 14.96M sh | +5.5% | — |
| FY2023 | — | $740.53K | $740.53K | — | 14.18M sh | −1.5% | 12.7% |
| FY2022 | — | $1.05M | $1.05M | — | 14.40M sh | −3.0% | 12.6% |
| FY2021 | — | $1.39M | $1.39M | — | 14.84M sh | −0.5% | 22.2% |
Segments
Products
LineFY2025ShareChange
Sancuso$11.91M27%+32.2%
Kristalose$10.54M24%−31.2%
Vibativ$9.48M21%+32.5%
Caldolor$4.66M10%−6.0%
Other$4.13M9.3%+210.1%
Product - Other$4.13M9.3%+210.1%
Product - Talicia$3.31M7.4%—
Other$490.78K1.1%+401.8%
Total$44.52M
Pharmaceutical preparations
Cumberland Pharmaceuticals Inc is the 133rd largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
GOSSGossamer Bio, Inc.$48.5M57.7%351.5%$68.0MPTGXProtagonist Therapeutics, Inc$46.0M89.4%282.8%$8.8BSEPNSepterna, Inc.$46.0M4,174.5%106.4%$2.0BAQSTAquestive Therapeutics, Inc.$44.5M22.6%188.1%$448.7M
CPIXCumberland Pharmaceuticals Inc (this company)$44.5M17.6%6.4%$98.4M
INBPIntegrated Biopharma Inc$43.9M19.3%6.5%$9.1MXLOXilio Therapeutics, Inc.$43.8M589.9%80.1%$58.3MWVEWave Life Sciences, Inc.$42.7M60.5%478.3%$622.3MBFRIBiofrontera Inc.$41.7M11.7%25.3%$14.0MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR